Winner F A Plus Perijoo
L-Isoleucine 0.22g · Glucose Monohydrate 7.08g +24 more
Solution · Prescription medication · Combination
JW Life Science Co., Ltd.
MFDS item code 202302603 · Approved 2023.08.31 · Insurance code 678901341,678901342,678901346
Correction of deficiencies in the supply of parenteral nutrition (amino acids, calories, etc.), water and electrolytes, and fatty acids
This medication is used to supply hydration, electrolytes, amino acids, calories, essential fatty acids, and omega-3 fatty acids intravenously to patients who are unable to take in nutrition orally or enough through the gastrointestinal tract. This helps improve the nutritional status of patients and adequately provides the necessary nutrients to aid in recovery.
The dose and infusion rate are determined based on the patient's ability to eliminate fat and metabolize nitrogen and glucose, as well as nutritional requirements; the dose and bag size are determined according to the patient's condition and body weight. Trace elements, vitamins, electrolytes, etc. may be added depending on the patient's condition. - Patients with normal nutritional status or mild metabolic stress: 0.10-0.15 g/kg/day as nitrogen (0.6-0.9g/kg as amino acids) - Patients experiencing moderate to severe metabolic stress, regardless of nutritional status: 0.15-0.25 g/kg/day as nitrogen (0.9-1.6 g/kg as amino acids) In very special cases (e.g., burns or a pronounced anabolic state), nitrogen requirements may be higher. Dose A daily dose of 20-40 mL/kg of this medicine corresponds to 0.124-0.248 g/kg of nitrogen (0.748-1.496 g/kg of amino acids) and a total of 13.401-26.802 kcal/kg (10.692-21.384 kcal/kg of non-protein calories). This meets the requirements of most patients. In obese patients, the dose should be based on predicted normal body weight. Infusion rate The infusion rate should not exceed 2.6 mL/kg per hour (equivalent to 0.167 g/kg of glucose, 0.097 g/kg of amino acids, and 0.072 g/kg of fat). The recommended infusion duration is 14-24 hours. Maximum daily dose The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The recommended maximum daily dose is 40mL/kg. The recommended maximum daily dose of 40 mL/kg provides 0.248 g/kg of nitrogen (1.496 g/kg as amino acids), 2.576 g/kg of glucose, 1.112 g/kg of fat, and a total of 26.802 kcal/kg (equivalent to 21.384 kcal/kg of non-protein calories). Method of administration Administer by intravenous infusion through a peripheral or central vein.
Use in children is not recommended.
This medication must be used strictly according to a physician's instructions. If allergic reactions such as fever, chills, rash, or difficulty breathing occur during use, administration must be stopped immediately. Since precipitates may form when used with intravenous calcium-containing preparations, it should not be administered through the same infusion line, and the equipment should be cleaned thoroughly before infusion. Particular caution is needed for premature infants or low-birth-weight infants, as there have been reported deaths when administered to premature infants with severe respiratory diseases. This medication should not be administered to individuals with allergies to fish, eggs, soybeans, or peanuts, or to patients with specific conditions such as severe hyperlipidemia, liver dysfunction, blood coagulation disorders, or renal failure. Neonates should not be co-administered with Ceftriaxone, and patients with hypersensitivity to soybean oil or nuts also require caution. Patients with renal failure, diabetes, pancreatitis, or liver dysfunction that affect fat metabolism should be administered with care. This medication can cause side effects such as fever, constipation, nausea, diarrhea, headache, and itching, as well as symptoms due to fat overload syndrome or amino acid overadministration. Patient condition should be closely monitored at the start of administration, and blood electrolytes and fluid status should be maintained normal. To reduce the risk of infection, aseptic procedures should be followed diligently, and the blood triglyceride levels should be periodically checked to prevent overdose during administration. During long-term administration, careful attention should also be paid to trace element balance, and it should not be administered simultaneously with blood. Regular monitoring of blood glucose, electrolytes, and liver function tests should be conducted, and patients with renal failure must manage phosphate and potassium intake. Patients with poor nutritional status should have fluid shifts and electrolyte changes closely observed, and administration should be started gradually. Patients with hyperglycemia may require insulin administration, and signs of phlebitis should be checked daily during peripheral venous infusion. This medication is not appropriate for children under 2 years of age, and there is insufficient safety data for pediatric use. Patients at risk of fat overload should check plasma lipid levels and adjust dosages as necessary. There are no safety data for use during pregnancy and lactation, so it should only be used when the therapeutic benefits outweigh the risks. Blood tests may be affected by administration, so blood tests should be performed 5-6 hours after administration. In case of overdose, the infusion rate should be slowed or stopped, and appropriate treatment should be received based on symptoms. Do not use if the packaging is damaged or if the solution is cloudy or separated, and maintain aseptic conditions during administration. This medication should be stored at a temperature between 1-30℃, avoiding freezing. It's safest to use immediately after mixing and store at 2-8℃ for use within 24 hours.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to protect it from air and moisture, and it is safest to store at room temperature between 1°C and 30°C. Proper storage will help maintain the effectiveness of the medication and prevent deterioration.
This medication consists of three compartments, which are divided into an internal bag and external packaging, with an oxygen absorber pouch in between. Each compartment contains glucose solution, amino acids, and electrolyte solution, and
240mL (A Solution: 119mL, B Solution: 90mL, C Solution: 31mL)/pack, 382mL (A Solution: 189mL, B Solution: 143mL, C Solution: 50mL)/pack, 505mL (A Solution: 250mL, B Solution: 189mL, C Solution: 66mL)/pack, 733mL (A Solution: 363mL, B Solution: 274mL, C Solution: 96mL)/pack, 1085mL (A Solution: 537mL, B Solution: 406mL, C Solution: 142mL)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
L-Isoleucine 0.22g · Glucose Monohydrate 7.08g +24 more
Solution · Prescription medication · Combination
JW Life Science Co., Ltd.
Glucose Monohydrate 462g · L-Isoleucine 6g +24 more
Solution · Prescription medication · Combination
JW Pharmaceutical Co., Ltd.
Glucose Monohydrate 143g · L-Isoleucine 6g +24 more
Solution · Prescription medication · Combination
JW Life Science Co., Ltd.
Glucose Monohydrate 9.138g · L-Isoleucine 0.38g +24 more
Solution · Prescription medication · Combination
JW Pharmaceutical Corp.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.